Multihance (Gadobenate Dimeglumine)

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of specific organ systems.

• Liver MRI: provides enhanced visualization of hepatic lesions and vascular structures.
• Central nervous system MRI: improves detection of brain tumors, vascular malformations, and inflammatory lesions.
• Cardiovascular MRI: enhances delineation of cardiac chambers, myocardial perfusion, and vascular anatomy.

• Gadobenate dimeglumine is a paramagnetic gadolinium chelate that binds weakly to plasma proteins, shortening T1 relaxation times of nearby water protons. This effect increases signal intensity on T1‑weighted MRI sequences, producing greater contrast between normal and pathological tissues and allowing more precise anatomical and functional assessment.

Adverse reactions may occur following intravenous administration of Multihance.

Common Side Effects

• Nausea
• Headache
• Injection‑site discomfort or warmth sensation
• Mild dizziness
• Metallic taste in the mouth
• Transient flushing

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis in patients with severe renal impairment
• Severe allergic reactions, including anaphylaxis
• Acute hypotension or cardiovascular collapse
• Pulmonary edema
• Severe skin reactions such as Stevens‑Johnson syndrome
• Cardiac arrest

Multihance should be used with careful clinical assessment and monitoring.

• Renal function assessment: evaluate glomerular filtration rate before administration.
• Pregnancy and lactation: use only if clearly needed; safety data are limited.
• History of hypersensitivity: avoid in patients with known allergy to gadolinium agents.
• Pediatric use: consider weight‑based dosing and monitor closely.
• Concomitant contrast agents: avoid overlapping use of multiple gadolinium agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed prior to using Multihance.

Major Interactions (Avoid)

• Concurrent use of multiple gadolinium‑based contrast agents: increases cumulative gadolinium exposure.
• Severe renal‑impairing medications (e.g., high‑dose NSAIDs, aminoglycosides) when combined with Multihance may heighten NSF risk.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal clearance of gadolinium.
• Calcium channel blockers: monitor for altered hemodynamics during injection.
• Other nephrotoxic drugs: observe renal function closely.
• Agents that cause hypersensitivity: increase vigilance for allergic reactions.